Journal article
Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors
Abstract
PURPOSE: Sorafenib and erlotinib are potent, orally administered receptor tyrosine kinase inhibitors with antiproliferative and antiangiogenic activities. Given their inhibitory target profile and efficacy as single agents, the combination of these drugs is of considerable interest in solid malignancies. This study aimed to determine the recommended phase II dose of this targeted combination, their toxicity profile, pharmacokinetic interaction, …
Authors
Duran I; Hotté SJ; Hirte H; Chen EX; MacLean M; Turner S; Duan L; Pond GR; Lathia C; Walsh S
Journal
Clinical Cancer Research, Vol. 13, No. 16, pp. 4849–4857
Publisher
American Association for Cancer Research (AACR)
Publication Date
August 15, 2007
DOI
10.1158/1078-0432.ccr-07-0382
ISSN
1078-0432